相关临床试验
1
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1901
进行中（未招募）
1
100.0%
暂无批准数据
- Researchers at Columbia Engineering developed CAPPSID, a novel cancer therapy that uses engineered Salmonella typhimurium bacteria to deliver oncolytic viruses directly into solid tumors while evading immune detection. - The system exploits bacteria's natural tumor-homing ability and shields the therapeutic virus from circulating antibodies that would otherwise neutralize it before reaching cancer cells. - Built-in safety mechanisms ensure the virus can only mature and spread within tumor tissue by creating a dependency on bacterial-produced proteases. - The approach demonstrated effectiveness in mouse models and represents the first engineered cooperation between bacteria and cancer-targeting viruses for therapeutic purposes.
- SurgiVance Inc. received a $2,245,000 National Cancer Institute Small Business Innovation Research Direct-to-Phase II grant to commercialize its "pathology lab-in-a-box" technology. - The platform enables direct-to-digital, in-office pathology using advanced imaging hardware and AI processing on whole tissue without traditional glass microscope slides. - Clinical studies will be conducted at NYU Langone Health, The Rockefeller University, Northwell Health, and Oregon Health & Science University targeting cancer at cellular and molecular levels. - The technology promises to deliver histopathologic diagnosis in minutes, potentially transforming cancer management and precision medicine through 3D molecular imaging biomarkers.
